Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants.

Détails

Ressource 1Télécharger: 25925382_BIB_788499DD20BB.pdf (744.64 [Ko])
Etat: Serval
Version: Final published version
ID Serval
serval:BIB_788499DD20BB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants.
Périodique
Critical Care
Auteur(s)
Faraoni D., Levy J.H., Albaladejo P., Samama C.M.
Collaborateur(s)
Groupe d'Intérêt en Hémostase Périopératoire
Contributeur(s)
Albaladejo P., Jebara S., Steib A., Godier A., Pernod G., Belisle S., Blais N., Bonhomme F., Borel-Derlon A., Borg JY., Bosson JL., Collet JP., De Maistre E., De Moerloose P., Fontana P., Gruel Y., Guay J., Huet Y., Ickx B., Jude B., Lasne D., Longrois D., Hardy JF., Marret E., Mismetti P., Motte S., Nathan N., Rosencher N., Samama CM., Jesel-Morel L., Schved JF., Schlumberger S., Sie P., Susen S., Van der Linden P., Vincentelli A., Zufferey P., Cohen A., Pitarch JV., Vanbelle E., Legal G., Laporte S., Lecompte TP., Ozier Y., Nguyen P., Roullet S., Faraoni D.
ISSN
1466-609X (Electronic)
ISSN-L
1364-8535
Statut éditorial
Publié
Date de publication
2015
Volume
19
Pages
203
Langue
anglais
Notes
Publication types: Journal Article
Résumé
Perioperative management of patients treated with the non-vitamin K antagonist oral anticoagulants is an ongoing challenge. Due to the lack of good clinical studies involving adequate monitoring and reversal therapies, management requires knowledge and understanding of pharmacokinetics, renal function, drug interactions, and evaluation of the surgical bleeding risk. Consideration of the benefit of reversal of anticoagulation is important and, for some low risk bleeding procedures, it may be in the patient's interest to continue anticoagulation. In case of major intra-operative bleeding in patients likely to have therapeutic or supra-therapeutic levels of anticoagulation, specific reversal agents/antidotes would be of value but are currently lacking. As a consequence, a multimodal approach should be taken which includes the administration of 25 to 50 U/kg 4-factor prothrombin complex concentrates or 30 to 50 U/kg activated prothrombin complex concentrate (FEIBA®) in some life-threatening situations. Finally, further studies are needed to clarify the ideal therapeutic intervention.
Pubmed
Web of science
Création de la notice
23/12/2015 15:12
Dernière modification de la notice
03/03/2018 18:30
Données d'usage